MD

Pediatrix Medical Group, Inc. (MD) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Pediatrix Medical Group, Inc. is a leading provider of physician services, including newborn, maternal-fetal, and pediatric subspecialty care, operating a national network of affiliated physicians across 37 states. The company operates as a single reportable segment.

Key Financial Metrics

Note: Debt figures include $192.4 million current portion and $398.3 million long-term portion of debt and finance lease liabilities as of March 31, 2026.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 3.9% ($17.8 million) driven by a 2.8% increase in same-unit revenue and contributions from recent acquisitions. Same-unit growth was fueled by improved collections, higher administrative fees, and increased patient acuity, partially offset by lower patient volumes in maternal-fetal and neonatology services.
• Profitability: Net income rose 42.6% year-over-year. Operating income increased 29.8% to $41.7 million. The effective tax rate decreased to 23.9% from 26.2%.
• Expense Management: Practice salaries and benefits increased 2.6% due to higher clinical compensation. Transformational and restructuring expenses decreased to $4.9 million from $6.6 million.
• Liquidity: Cash and cash equivalents decreased to $205.8 million from $375.2 million at year-end 2025. Working capital declined by $160.2 million, primarily due to the reclassification of the Term A Loan to current liabilities.
• Capital Allocation: The company repurchased 1.0 million shares for $19.9 million under its August 2025 program. It also completed the acquisition of a maternal-fetal medicine practice for $7.9 million.

Outlook, Risks, and Management Commentary

• Guidance: The filing does not provide specific numerical guidance for the full year 2026. Management anticipates funds from operations and current cash will be sufficient for working capital, acquisitions, and debt obligations for the next 12 months.
• Regulatory Risks: Significant risks include the impact of the "One Big Beautiful Bill Act" signed in July 2025, which reforms Medicaid by eliminating financial incentives for expansion and imposing work requirements. The Congressional Budget Office estimates this could cut federal spending by $1 trillion and remove 10.5 million people from coverage by 2034.
• Surprise Billing: The No Surprises Act (NSA) continues to impact reimbursement rates for out-of-network services, potentially limiting revenue recovery.
• Legal Contingencies: The company faces ongoing medical malpractice claims and government audits. While management believes outcomes will not be materially adverse, unfavorable resolutions could impact financial results. Total professional liability risk exposure is $270.9 million.
• Executive Transition: Mary Ann E. Moore, Executive Vice President and General Counsel, is transitioning from her role, with the change expected before the end of 2026.

Investor Verification Checklist

• Medicaid Reform Impact: Verify the specific financial modeling regarding the "One Big Beautiful Bill Act" and its potential reduction in patient volume and reimbursement rates.
• Debt Maturity Profile: Confirm the ability to service the $190.6 million Term A Loan maturing in February 2027 and the $400 million 2030 Notes.
• Days Sales Outstanding (DSO): Monitor DSO trends (currently 42.5 days) to ensure collection efficiency remains stable despite revenue growth.
• Share Repurchase Capacity: Track the remaining $146.3 million available under the current repurchase program and its impact on future liquidity.
• Professional Liability Reserves: Review actuarial assumptions for the $270.9 million professional liability reserve to assess adequacy against potential claims.